On October 9, 2017, PPG Industries’ (PPG) glass-faced acrylic windshields received Parts Manufacturer Approval from the Federal Aviation Administration.
On October 10, 2017, Air Products and Chemicals (APD) announced that it would continue operating and maintaining Barrick’s oxygen plant in Elko, Nevada.
On October 12, 2017, PolyOne announced that it would pay a quarterly cash dividend of $0.175—a 30% increase on a YoY basis from $0.54 to $0.70.
Grace remained flat, fell 0.10%, and closed at $72.50 last week. Its stock traded 2.20% above the 100-day moving average price of $70.93.
It appears that the Kingsport incident had a negative impact on the stock. Eastman Chemical fell 2.60% and closed at $88.65.
On October 13, Praxair announced that it signed a long-term contract with Shanghai Huali Microelectronics. Praxair will build two new air separation plants.
Pacific Gas & Electric, which is an investor-owned electric utility with publicly traded stock, was the S&P 500’s top loser on October 13, 2017.
Hewlett-Packard was the S&P 500’s top gainer on October 13. The market sentiment improved after Hewlett-Packard released its strong 2018 outlook.
Of the 15 analysts covering E*TRADE Financial (ETFC) in October 2017, seven analysts gave a “strong buy” rating on the stock, and four analysts gave “buy” recommendations.
E*TRADE Financial Corporation (ETFC) has a price-to-earnings ratio of ~21.0x on a trailing-12-month (or TTM) basis.
E*TRADE reported deposits of ~$40.1 billion on June 30, 2017, compared to ~$31.7 billion on December 31, 2016, reflecting a 26% rise.
E*TRADE Financial’s return on equity was ~9.7% over the last 12 months.
E*TRADE Financial generated an ~1.1% return on its assets over the last 12 months.
E*TRADE Financial (ETFC) reported total net revenues of ~$1.1 billion in 1H17 compared to $946.0 million in 1H16, reflecting a 19% increase.
In 2Q17, Sanofi’s (SNY) Consumer Healthcare business reported revenues of 1.2 billion euros, which is a 42.5% YoY rise on a CER basis and a YoY fall of 0.10% on a CER and CS basis.
In 2Q17, Sanofi’s (SNY) diabetes business reported revenues of 1.7 billion euros, which is a YoY (year-over-year) fall of 12.2% on a CER (constant exchange rate) basis.
In 2Q17, Sanofi’s (SNY) vaccine business reported revenues of 1.0 billion euros, which is a YoY rise of 26.2% on a CER basis and 19.2% on a CER and CS basis.
Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.
Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).
In 2Q17, Sanofi’s (SNY) Sanofi Genzyme, its specialty care business, reported revenues of 1.7 billion euros, which is a 13.6% rise YoY (year-over-year).